BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis
USA - NASDAQ:BMGL - VGG0864B1031 - Common Stock
1.4 USD
-0.06 (-4.24%)
1.4 USD
0 (0%)
Taking everything into account, BMGL scores 3 out of 10 in our fundamental rating. BMGL was compared to 100 industry peers in the Health Care Providers & Services industry. BMGL has an average financial health and profitability rating. BMGL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BMGL had positive earnings in the past year.
In the past year BMGL has reported a negative cash flow from operations.
1.2 Ratios
BMGL's Return On Assets of 11.76% is amongst the best of the industry. BMGL outperforms 97.00% of its industry peers.
BMGL has a Return On Equity of 24.18%. This is amongst the best in the industry. BMGL outperforms 92.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 36.92%, BMGL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
BMGL had an Average Return On Invested Capital over the past 3 years of 29.84%. This is significantly above the industry average of 9.45%.
The last Return On Invested Capital (36.92%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.76% | ||
| ROE | 24.18% | ||
| ROIC | 36.92% |
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
1.3 Margins
BMGL has a Profit Margin of 11.64%. This is amongst the best in the industry. BMGL outperforms 98.00% of its industry peers.
BMGL has a Operating Margin of 32.46%. This is amongst the best in the industry. BMGL outperforms 98.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.46% | ||
| PM (TTM) | 11.64% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BMGL remains at a similar level compared to 1 year ago.
BMGL has a better debt/assets ratio than last year.
2.2 Solvency
BMGL has an Altman-Z score of 3.82. This indicates that BMGL is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.82, BMGL is doing good in the industry, outperforming 73.00% of the companies in the same industry.
BMGL has a Debt/Equity ratio of 0.55. This is a neutral value indicating BMGL is somewhat dependend on debt financing.
BMGL has a Debt to Equity ratio of 0.55. This is in the better half of the industry: BMGL outperforms 61.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.82 |
ROIC/WACC4.23
WACC8.72%
2.3 Liquidity
BMGL has a Current Ratio of 1.88. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.88, BMGL is in the better half of the industry, outperforming 72.00% of the companies in the same industry.
A Quick Ratio of 1.87 indicates that BMGL should not have too much problems paying its short term obligations.
BMGL's Quick ratio of 1.87 is fine compared to the rest of the industry. BMGL outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.87 |
3. Growth
3.1 Past
The earnings per share for BMGL have decreased strongly by -43.56% in the last year.
The Revenue has been growing slightly by 1.99% in the past year.
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.00 indicates a rather expensive valuation of BMGL.
BMGL's Price/Earnings ratio is a bit cheaper when compared to the industry. BMGL is cheaper than 65.00% of the companies in the same industry.
BMGL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20 | ||
| Fwd PE | N/A |
4.2 Price Multiples
BMGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMGL is cheaper than 96.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.97 |
4.3 Compensation for Growth
The decent profitability rating of BMGL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BMGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.4
-0.06 (-4.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.7%
Inst Owner ChangeN/A
Ins Owners13.65%
Ins Owner ChangeN/A
Market Cap26.31M
Revenue(TTM)15.09M
Net Income(TTM)1.76M
AnalystsN/A
Price TargetN/A
Short Float %4.17%
Short Ratio2.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20 | ||
| Fwd PE | N/A | ||
| P/S | 2.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.72 | ||
| P/tB | 4.72 | ||
| EV/EBITDA | 3.97 |
EPS(TTM)0.07
EY5%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.62
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.76% | ||
| ROE | 24.18% | ||
| ROCE | 67.42% | ||
| ROIC | 36.92% | ||
| ROICexc | 1026.25% | ||
| ROICexgc | 1026.25% | ||
| OM | 32.46% | ||
| PM (TTM) | 11.64% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.73 | ||
| Cap/Depr | 2.99% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 27.55 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.87 | ||
| Altman-Z | 3.82 |
F-Score3
WACC8.72%
ROIC/WACC4.23
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A
BASEL MEDICAL GROUP LTD / BMGL FAQ
What is the fundamental rating for BMGL stock?
ChartMill assigns a fundamental rating of 3 / 10 to BMGL.
What is the valuation status of BASEL MEDICAL GROUP LTD (BMGL) stock?
ChartMill assigns a valuation rating of 2 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.
How profitable is BASEL MEDICAL GROUP LTD (BMGL) stock?
BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 6 / 10.
What are the PE and PB ratios of BASEL MEDICAL GROUP LTD (BMGL) stock?
The Price/Earnings (PE) ratio for BASEL MEDICAL GROUP LTD (BMGL) is 20 and the Price/Book (PB) ratio is 4.72.